# Axsome Therapeutics Inc. (AXSM) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $139.61, market value $7.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Axsome Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.90**. A PEG of 0.90 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 8.5×**. Each dollar of revenue is priced at 8.5×.
- **Price / book: 69.6×**. The shares trade at 69.6× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -1.1%** (5-yr avg -3.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -17.5%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -28.7%**. The company reported a net loss over the last twelve months.
- **Return on equity: -207.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 254.4%**. Return on all capital, debt included, is 254.4%: comfortably above what that capital costs.
- **Return on assets: -22.8%**. Each dollar of assets produces -22.8% of profit.

## Growth
- **Revenue growth (1 yr): 65.5%** (3-yr 133.7%/yr). Revenue grew 65.5% over the last year.
- **EPS growth (1 yr): 38.6%**. Earnings per share rose 38.6%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 2.13**. Debt is 2.13 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Current ratio: 1.55** (quick 1.55). Current assets cover the next year's liabilities 1.55 times.
- **Altman Z-score: 7.99**. A Z-score of 7.99 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Axsome Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (21 analysts). 21 analysts cover Axsome Therapeutics Inc.; the consensus is strong_buy, with an average price target of $277.86 (+99% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 0.8%** (YTD -25.5%, 3-mo -35.6%). The shares are up 0.8% over twelve months including dividends.
- **From 52-week high: -46.3%** (13.5% above the low). Trading 46% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 20**. An RSI of 20 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 0.59** (volatility 45%). Beta of 0.59 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AXSM · Page: https://foliofundamentals.com/stocks/axsm

Not investment advice.